The colorectal cancer is one of the leading causes of death globally. In the recent years, the availability of multi- gene panel testing has provided a promising tool to more precisely stratify patients for their CRC risks. There has been significant advances with respect to the efficacy of various methods of screening over the past decade. In the United States, multiple professional societies recommend screening for CRC for the individuals who are aged between 50 to 75 years. However, the guidelines from American Cancer Society recommends starting CRC screening at age 45 years. Current modalities for colorectal cancer screening include fecal occult-blood testing, flexible sigmoidoscopy, colonoscopy, and double-contrast barium enema. Among these, colonoscopy is becoming the dominant modality for its efficacy and continuing technical refinements. The emerging technologies, such as stool DNA tests and blood tests, hold promise for the future but cannot be recommended for screening at present.

1. INTRODUCTION 

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY 

4. MARKET DYNAMICS 

5. MARKET SEGMENTATION 

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE 

7. MARKET OPPORTUNITIES AND FUTURE TRENDS